Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares

Bioventus Inc. (NASDAQ:BVS) Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. This represents a 21.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Bioventus Trading Up 0.2%

Shares of BVS traded up $0.02 during trading hours on Friday, reaching $8.62. The stock had a trading volume of 286,351 shares, compared to its average volume of 334,578. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. Bioventus Inc. has a 52 week low of $5.81 and a 52 week high of $10.13. The firm has a 50-day moving average of $8.25 and a 200 day moving average of $7.54. The company has a market cap of $716.75 million, a P/E ratio of 12.65 and a beta of 0.78.

Bioventus (NASDAQ:BVS) last posted its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.02. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.The firm had revenue of $157.90 million for the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BVS shares. Barrington Research boosted their price objective on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, March 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Bioventus in a report on Monday, December 29th. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Finally, Craig Hallum upped their price target on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, Bioventus has an average rating of “Buy” and a consensus price target of $14.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Marshall Wace LLP raised its position in Bioventus by 0.4% in the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after buying an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after acquiring an additional 1,887 shares during the last quarter. Deutsche Bank AG grew its stake in shares of Bioventus by 8.2% during the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after acquiring an additional 1,908 shares in the last quarter. Finally, Covestor Ltd raised its holdings in shares of Bioventus by 28.0% in the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares during the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.